Testowanie immunoterapii niwolumabem i ipilimumabem z lekiem celowanym kabozantynibem lub bez niego w nawrotowym, przerzutowym lub nieuleczalnym raku nosogardzieli
Randomizowane badanie fazy 2 niwolumabu i ipilimumabu z kabozantynibem lub bez niego u pacjentów z zaawansowanym rakiem nosogardła, u których doszło do progresji po leczeniu platyną i immunoterapii
This phase II trial tests how well nivolumab and ipilimumab immunotherapy with or without cabozantinib works in treating patients with nasopharyngeal cancer that has come back (after a period of improvement) (recurrent), has spread from where it first started (primary site) to other places in the body (metastatic), or for which no treatment is currently available (incurable). Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cabozantinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread of cancer cells. Giving immunotherapy with nivolumab and ipilimumab and targeted therapy with cabozantinib may help shrink and stabilize nasopharyngeal cancer.
Przegląd badań
Status
Status
Warunki
Warunki
Interwencja / Leczenie
Interwencja / Leczenie
Szczegółowy opis
PRIMARY OBJECTIVE:
I. To determine if the progression-free survival (PFS) of the triplet combination (cabozantinib S-malate, nivolumab, and ipilimumab [CaboNivoIpi]) is more favorable than the doublet (nivolumab and ipilimumab [NivoIpi]).
SECONDARY OBJECTIVES:
I. To compare safety and tolerability between the two arms (Common Terminology Criteria for Adverse Events [CTCAE] version [v]5.0.).
II. To compare overall response rate (ORR) between the two arms via both Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and immune-modified Response Evaluation Criteria in Solid Tumors (iRECIST) criteria.
III. To compare overall survival (OS) between the two arms. IV. To assess response by primary or acquired PD-1/L1 inhibitor resistance in the prior line of therapy.
EXPLORATORY OBJECTIVE:
I. To evaluate molecular and immunologic predictors of response (Epstein-Barr virus [EBV] viral load; PD-L1 score) between arms.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM A: Patients receive nivolumab intravenously (IV) over 30 minutes and ipilimumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo computed tomography (CT) or magnetic resonance imaging (MRI) and collection of blood samples throughout the trial.
ARM B: Patients receive nivolumab IV over 30 minutes and ipilimumab IV over 30 minutes on day 1 and cabozantinib S-malate orally (PO) daily on days 1-28 of each cycle. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients may continue with cabozantinib S-malate after 2 years per treating investigator. Patients undergo CT or MRI and collection of blood samples throughout the trial.
After completion of study treatment, patients are followed up every 8-12 weeks until progression of disease occurs or a new non-protocol anti-cancer therapy is initiated and then every 6 months for up to 2 years.
Typ studiów
Typ studiów
Zapisy (Szacowany)
Zapisy
Faza
Faza
- Faza 2
Kontakty i lokalizacje
Lokalizacje studiów
-
-
California
-
Irvine, California, Stany Zjednoczone, 92612
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
-
Los Angeles, California, Stany Zjednoczone, 90033
- USC / Norris Comprehensive Cancer Center
-
Los Angeles, California, Stany Zjednoczone, 90020
- Keck Medicine of USC Koreatown
-
Los Angeles, California, Stany Zjednoczone, 90033
- Los Angeles General Medical Center
-
Newport Beach, California, Stany Zjednoczone, 92663
- USC Norris Oncology/Hematology-Newport Beach
-
Orange, California, Stany Zjednoczone, 92868
- UC Irvine Health/Chao Family Comprehensive Cancer Center
-
Palo Alto, California, Stany Zjednoczone, 94304
- Stanford Cancer Institute Palo Alto
-
-
Georgia
-
Atlanta, Georgia, Stany Zjednoczone, 30308
- Emory University Hospital Midtown
-
-
Idaho
-
Boise, Idaho, Stany Zjednoczone, 83706
- Saint Alphonsus Cancer Care Center-Boise
-
Caldwell, Idaho, Stany Zjednoczone, 83605
- Saint Alphonsus Cancer Care Center-Caldwell
-
Coeur d'Alene, Idaho, Stany Zjednoczone, 83814
- Kootenai Health - Coeur d'Alene
-
Nampa, Idaho, Stany Zjednoczone, 83687
- Saint Alphonsus Cancer Care Center-Nampa
-
Post Falls, Idaho, Stany Zjednoczone, 83854
- Kootenai Clinic Cancer Services - Post Falls
-
Sandpoint, Idaho, Stany Zjednoczone, 83864
- Kootenai Clinic Cancer Services - Sandpoint
-
-
Illinois
-
Chicago, Illinois, Stany Zjednoczone, 60611
- Northwestern University
-
Chicago, Illinois, Stany Zjednoczone, 60637
- University of Chicago Comprehensive Cancer Center
-
Chicago, Illinois, Stany Zjednoczone, 60612
- University of Illinois
-
Danville, Illinois, Stany Zjednoczone, 61832
- Carle at The Riverfront
-
DeKalb, Illinois, Stany Zjednoczone, 60115
- Northwestern Medicine Cancer Center Kishwaukee
-
Effingham, Illinois, Stany Zjednoczone, 62401
- Carle Physician Group-Effingham
-
Evanston, Illinois, Stany Zjednoczone, 60201
- NorthShore University HealthSystem-Evanston Hospital
-
Geneva, Illinois, Stany Zjednoczone, 60134
- Northwestern Medicine Cancer Center Delnor
-
Glenview, Illinois, Stany Zjednoczone, 60026
- NorthShore University HealthSystem-Glenbrook Hospital
-
Glenview, Illinois, Stany Zjednoczone, 60026
- Northwestern Medicine Glenview Outpatient Center
-
Grayslake, Illinois, Stany Zjednoczone, 60030
- Northwestern Medicine Grayslake Outpatient Center
-
Harvey, Illinois, Stany Zjednoczone, 60426
- Ingalls Memorial Hospital
-
Highland Park, Illinois, Stany Zjednoczone, 60035
- NorthShore University HealthSystem-Highland Park Hospital
-
Lake Forest, Illinois, Stany Zjednoczone, 60045
- Northwestern Medicine Lake Forest Hospital
-
Mattoon, Illinois, Stany Zjednoczone, 61938
- Carle Physician Group-Mattoon/Charleston
-
New Lenox, Illinois, Stany Zjednoczone, 60451
- UC Comprehensive Cancer Center at Silver Cross
-
Orland Park, Illinois, Stany Zjednoczone, 60462
- University of Chicago Medicine-Orland Park
-
Orland Park, Illinois, Stany Zjednoczone, 60462
- Northwestern Medicine Orland Park
-
Urbana, Illinois, Stany Zjednoczone, 61801
- Carle Cancer Center
-
Warrenville, Illinois, Stany Zjednoczone, 60555
- Northwestern Medicine Cancer Center Warrenville
-
-
Iowa
-
Ankeny, Iowa, Stany Zjednoczone, 50023
- UI Health Care Mission Cancer and Blood - Ankeny Clinic
-
Clive, Iowa, Stany Zjednoczone, 50325
- Mercy Cancer Center-West Lakes
-
Clive, Iowa, Stany Zjednoczone, 50325
- UI Health Care Mission Cancer and Blood - West Des Moines Clinic
-
Council Bluffs, Iowa, Stany Zjednoczone, 51503
- Heartland Oncology and Hematology LLP
-
Council Bluffs, Iowa, Stany Zjednoczone, 51503
- Methodist Jennie Edmundson Hospital
-
Council Bluffs, Iowa, Stany Zjednoczone, 51503
- Nebraska Cancer Specialists/Oncology Hematology West PC - MEJ
-
Des Moines, Iowa, Stany Zjednoczone, 50309
- Iowa Methodist Medical Center
-
Des Moines, Iowa, Stany Zjednoczone, 50314
- Mercy Medical Center - Des Moines
-
Des Moines, Iowa, Stany Zjednoczone, 50309
- UI Health Care Mission Cancer and Blood - Des Moines Clinic
-
Des Moines, Iowa, Stany Zjednoczone, 50314
- UI Health Care Mission Cancer and Blood - Laurel Clinic
-
Waukee, Iowa, Stany Zjednoczone, 50263
- UI Health Care Mission Cancer and Blood - Waukee Clinic
-
-
Massachusetts
-
Boston, Massachusetts, Stany Zjednoczone, 02111
- Tufts Medical Center
-
-
Minnesota
-
Bemidji, Minnesota, Stany Zjednoczone, 56601
- Sanford Joe Lueken Cancer Center
-
-
Missouri
-
St Louis, Missouri, Stany Zjednoczone, 63128
- Mercy Hospital South
-
-
Montana
-
Anaconda, Montana, Stany Zjednoczone, 59711
- Community Hospital of Anaconda
-
Billings, Montana, Stany Zjednoczone, 59101
- Billings Clinic Cancer Center
-
Bozeman, Montana, Stany Zjednoczone, 59715
- Bozeman Health Deaconess Hospital
-
Great Falls, Montana, Stany Zjednoczone, 59405
- Benefis Sletten Cancer Institute
-
Kalispell, Montana, Stany Zjednoczone, 59901
- Logan Health Medical Center
-
Missoula, Montana, Stany Zjednoczone, 59804
- Community Medical Center
-
-
Nebraska
-
Omaha, Nebraska, Stany Zjednoczone, 68114
- Nebraska Methodist Hospital
-
Omaha, Nebraska, Stany Zjednoczone, 68114
- Oncology Associates PC
-
Omaha, Nebraska, Stany Zjednoczone, 68114
- Nebraska Cancer Specialists/Oncology Hematology West PC - MECC
-
-
New Jersey
-
Basking Ridge, New Jersey, Stany Zjednoczone, 07920
- Memorial Sloan Kettering Basking Ridge
-
Middletown, New Jersey, Stany Zjednoczone, 07748
- Memorial Sloan Kettering Monmouth
-
Montvale, New Jersey, Stany Zjednoczone, 07645
- Memorial Sloan Kettering Bergen
-
-
New York
-
Commack, New York, Stany Zjednoczone, 11725
- Memorial Sloan Kettering Commack
-
Harrison, New York, Stany Zjednoczone, 10604
- Memorial Sloan Kettering Westchester
-
New York, New York, Stany Zjednoczone, 10065
- Memorial Sloan Kettering Cancer Center
-
Uniondale, New York, Stany Zjednoczone, 11553
- Memorial Sloan Kettering Nassau
-
-
North Carolina
-
Chapel Hill, North Carolina, Stany Zjednoczone, 27599
- UNC Lineberger Comprehensive Cancer Center
-
Charlotte, North Carolina, Stany Zjednoczone, 28204
- Novant Health Presbyterian Medical Center
-
Huntersville, North Carolina, Stany Zjednoczone, 28078
- Novant Health Cancer Institute - Huntersville
-
Matthews, North Carolina, Stany Zjednoczone, 28105
- Novant Health Cancer Institute - Matthews
-
Mooresville, North Carolina, Stany Zjednoczone, 28117
- Novant Health Cancer Institute - Mooresville
-
-
North Dakota
-
Bismarck, North Dakota, Stany Zjednoczone, 58501
- Sanford Bismarck Medical Center
-
Fargo, North Dakota, Stany Zjednoczone, 58122
- Sanford Roger Maris Cancer Center
-
Fargo, North Dakota, Stany Zjednoczone, 58122
- Sanford Broadway Medical Center
-
-
Ohio
-
Cincinnati, Ohio, Stany Zjednoczone, 45220
- Good Samaritan Hospital - Cincinnati
-
-
Oklahoma
-
Lawton, Oklahoma, Stany Zjednoczone, 73505
- Cancer Centers of Southwest Oklahoma Research
-
Oklahoma City, Oklahoma, Stany Zjednoczone, 73104
- University of Oklahoma Health Sciences Center
-
Tulsa, Oklahoma, Stany Zjednoczone, 74146
- Oklahoma Cancer Specialists and Research Institute-Tulsa
-
-
Oregon
-
Ontario, Oregon, Stany Zjednoczone, 97914
- Saint Alphonsus Cancer Care Center-Ontario
-
Portland, Oregon, Stany Zjednoczone, 97239
- Oregon Health and Science University
-
-
South Carolina
-
Charleston, South Carolina, Stany Zjednoczone, 29425
- Medical University of South Carolina
-
-
South Dakota
-
Sioux Falls, South Dakota, Stany Zjednoczone, 57117-5134
- Sanford USD Medical Center - Sioux Falls
-
Sioux Falls, South Dakota, Stany Zjednoczone, 57104
- Sanford Cancer Center Oncology Clinic
-
-
Tennessee
-
Nashville, Tennessee, Stany Zjednoczone, 37232
- Vanderbilt University/Ingram Cancer Center
-
-
Virginia
-
Richmond, Virginia, Stany Zjednoczone, 23235
- VCU Massey Cancer Center at Stony Point
-
Richmond, Virginia, Stany Zjednoczone, 23298
- VCU Massey Comprehensive Cancer Center
-
-
West Virginia
-
Morgantown, West Virginia, Stany Zjednoczone, 26506
- West Virginia University Healthcare
-
Parkersburg, West Virginia, Stany Zjednoczone, 26101
- Camden Clark Medical Center
-
-
Wisconsin
-
Eau Claire, Wisconsin, Stany Zjednoczone, 54701
- Marshfield Medical Center-EC Cancer Center
-
Marshfield, Wisconsin, Stany Zjednoczone, 54449
- Marshfield Medical Center-Marshfield
-
Minocqua, Wisconsin, Stany Zjednoczone, 54548
- Marshfield Medical Center - Minocqua
-
Rice Lake, Wisconsin, Stany Zjednoczone, 54868
- Marshfield Medical Center-Rice Lake
-
Stevens Point, Wisconsin, Stany Zjednoczone, 54482
- Marshfield Medical Center-River Region at Stevens Point
-
Weston, Wisconsin, Stany Zjednoczone, 54476
- Marshfield Medical Center - Weston
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
-
Patients must have histologically documented nasopharyngeal carcinoma (NPC) regardless of World Health Organization (WHO) classification (keratinizing squamous cell carcinoma, non-keratinizing, or basaloid squamous cell carcinoma) and regardless of association with Epstein-Barr virus (EBV) and/or human papillomavirus (HPV)
-
Recurrent, metastatic and incurable disease treated with platinum-gemcitabine and prior PD-1/L1 blockade (as first or second-line therapy)
-
Patients are eligible regardless of prior smoking history, p16 immunohistochemistry (IHC) status, PD-L1 expression status, EBV tumor status, EBV viral load at baseline, or tumor genomic alteration status
-
Patients must have at least one measurable lesion (by RECIST v1.1) which has not been previously irradiated that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions as >= 10 mm (>= 1 cm) (and short axis for nodal lesions, LN >= 15 mm) with CT scan, MRI, or calipers by clinical exam
-
Patients may have had no more than 2 prior lines of prior systemic therapy for recurrent, metastatic NPC
-
No prior VEGFR targeted therapy permitted
-
Age >= 18 years
-
Eastern Cooperative Oncology Group Performance (ECOG) performance status 0-2
-
Absolute neutrophil count (ANC) >= 1,000/mm^3
-
Hemoglobin >= 9 g/dL
-
Platelet count >= 100,000/mm^3
-
Creatinine or creatinine clearance =< 1.5 mg/dL or >= 30 Modification of Diet in Renal Disease (MDRD)
-
Total bilirubin =< 1.5 x institutional upper limit of normal (ULN); except subjects with Gilbert syndrome who can have a total bilirubin < 3 mg/dL
-
Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGT]) =< 3 x upper limit of normal (ULN)
- Up to =< 5 allowed with liver metastases
-
Not pregnant and not nursing, because this study involves an investigational agent whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are unknown. Therefore, for women of childbearing potential only, a negative urine or serum pregnancy test, per institution standard, done =< 7 days prior to registration is required.
- Pregnant women are excluded from this study because nivolumab, ipilimumab, and cabozantinib are all Class C or D agents with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants, secondary to treatment of the mother with any of the study agents, breastfeeding should be discontinued if the mother is treated with as part of this study (in either arm)
-
No active tumor bleeding: or radiographic evidence of major blood vessel infiltration as judged by the treating investigator
-
Prior -anti-cancer therapy is allowed: Patients need to be recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > grade 1), with the exception of alopecia. Any life-threatening events clearly attributable to prior immunotherapy exposure that have a high possibility of recurring should warrant exclusion: including severe pneumonitis, grade 4 bullous dermatitis/drug reaction with eosinophilia and systemic symptoms (DRESS), neurologic events such as autoimmune encephalitis transverse myelitis, and/or myocarditis. Maintenance hormonal replacement or long-term hormonal therapy exposure is permitted.
-
No chemotherapy or radiotherapy within 3 weeks (6 weeks for nitrosoureas or mitomycin C) prior to registration. Palliative (limited-field) radiation therapy is permitted, if all of the following criteria are met:
- Repeat imaging demonstrates no new sites of bone metastases.
- The lesion being considered for palliative radiation is not a target lesion
-
-
No patients with a prior malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of the investigational regimen
-
Brain metastases allowed: Patients with treated brain metastases are eligible if follow-up brain imaging 3 weeks after central nervous system (CNS)-directed therapy shows no evidence of progression. Patients with new or progressive brain metastases (active brain metastases) or leptomeningeal disease are eligible if the treating physician determines that immediate CNS specific treatment is not required and is unlikely to be required during the first cycle of therapy
-
Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months prior to registration are eligible for this trial
-
For patients with evidence of chronic hepatitis B (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
- Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently receiving treatment, they are eligible if they have an undetectable HCV viral load
-
Solid organ or tissue transplant is allowed: - subsequent therapy with nivolumab increases the risk of organ/tissue rejection. Patients must be instructed that it is crucial they stay in touch with their transplant team during treatment
-
No active autoimmune disease: or history of autoimmune disease that might recur, and which may affect vital organ function or require immune suppressive treatment including systemic corticosteroids. These include but are not limited to patients with a history of
- Immune related neurologic disease,
- Multiple sclerosis,
- Autoimmune (demyelinating) neuropathy,
- Guillain-Barre syndrome (GBS),
- Myasthenia gravis;
- Systemic autoimmune disease such as SLE,
- Connective tissue diseases,
- Scleroderma, inflammatory bowel disease (IBD),
- Crohn's, ulcerative colitis,
- Patients with a history of toxic epidermal necrolysis (TEN),
- Stevens-Johnson syndrome, or phospholipid syndrome should be excluded because of the risk of recurrence or exacerbation of disease
-
Patients with vitiligo, endocrine deficiencies including thyroiditis managed with replacement hormones including physiologic corticosteroids are eligible
-
Patients with rheumatoid arthritis and other arthropathies, Sjogren's syndrome, and psoriasis controlled with topical medication and patients with only positive serology, such as antinuclear antibodies (ANA) or anti-thyroid antibodies, should be evaluated for the presence of target organ involvement and potential need for systemic treatment but should otherwise be eligible
-
Pneumonitis should be evaluated for the nature of the disease process, need for treatment prior study treatment, and the risk of exacerbation with study treatment
-
Able to swallow oral medication: No known medical condition causing an inability to swallow oral formulations of agents
-
No condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of study registration. Patients are permitted the use of topical, ocular, intra-articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption). Adrenal replacement steroid doses > 10 mg daily prednisone are permitted. A brief (less than 3 weeks) course of corticosteroids for prophylaxis (e.g., contrast dye allergy) or for treatment of non-autoimmune conditions (e.g., delayed-type hypersensitivity reaction caused by a contact allergen) is permitted
-
Concomitant anticoagulation with coumarin agents (e.g., warfarin), direct thrombin inhibitors (e.g., dabigatran), direct factor Xa inhibitor betrixaban, or platelet inhibitors (e.g., clopidogrel) is prohibited. Allowed anticoagulants are the following:
- Prophylactic use of low-dose aspirin for cardio-protection (per local applicable guidelines) and low-dose low molecular weight heparins (LMWH).
- Therapeutic doses of LMWH or anticoagulation with direct factor Xa inhibitors rivaroxaban, edoxaban, or apixaban in subjects without known brain metastases who are on a stable dose of the anticoagulant for at least 1 week before first dose of study treatment without clinically significant hemorrhagic complications from the anticoagulation regimen or the tumor
-
Concomitant use of any medications or substances that are strong inhibitors or inducers of CYP3A4 is discouraged; if unavoidable, the dose of cabozantinib on study should be adjusted accordingly. Any complementary medications (e.g., herbal supplements or traditional Chinese medicines) intended to treat the disease under study are prohibited
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Brak (otwarta etykieta)
Liczba ramion
Broń i interwencje
Grupa uczestników / ArmGrupa uczestników / Arm |
Interwencja / LeczenieInterwencja / Leczenie |
|---|---|
|
Aktywny komparator: Arm A (nivolumab, ipilimumab)
Patients receive nivolumab IV over 30 minutes and ipilimumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo CT or MRI and collection of blood samples throughout the trial. |
Given IV
Inne nazwy:
Undergo MRI
Inne nazwy:
Given IV
Inne nazwy:
Undergo collection of blood samples
Inne nazwy:
Undergo CT scan
Inne nazwy:
|
|
Eksperymentalny: Arm B (nivolumab, ipilimumab, cabozantinib)
Patients receive nivolumab IV over 30 minutes and ipilimumab IV over 30 minutes on day 1 and cabozantinib S-malate PO daily on days 1-28 of each cycle. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients may continue with cabozantinib S-malate after 2 years per treating investigator. Patients undergo CT or MRI and collection of blood samples throughout the trial. |
Given IV
Inne nazwy:
Undergo MRI
Inne nazwy:
Given PO
Inne nazwy:
Given IV
Inne nazwy:
Undergo collection of blood samples
Inne nazwy:
Undergo CT scan
Inne nazwy:
|
Co mierzy badanie?
Podstawowe miary wyniku
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Progression-free survival (PFS)
Ramy czasowe: From randomization to the first of either progression or death from any cause, or censored at last known tumor assessment date, assessed up to 2 years
|
PFS will be estimated using the Kaplan-Meier method, where the log-rank test will be used to compare the 2 treatment arms. |
From randomization to the first of either progression or death from any cause, or censored at last known tumor assessment date, assessed up to 2 years
|
Miary wyników drugorzędnych
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Overall survival (OS)
Ramy czasowe: From randomization to death from any cause, or censored at last known follow-up, assessed up to 2 years
|
OS will be estimated using the Kaplan-Meier method, where the log-rank test will be used to compare the 2 treatment arms. |
From randomization to death from any cause, or censored at last known follow-up, assessed up to 2 years
|
|
Incidence of adverse events
Ramy czasowe: Up to 2 years
|
The maximum grade for each type of adverse event will be summarized using Common Terminology Criteria for Adverse Events version 5.0. The frequency and percentage of grade 3+ adverse events will be compared between the 2 treatment arms. Comparisons between arms will be made by using either the chi-square or Fisher's exact test. |
Up to 2 years
|
|
Response by subgroups of interest
Ramy czasowe: Up to 2 years
|
Will also report and compare the overall response rate (ORR) between different subgroups of interest (primary or acquired PD-1/L1 inhibitor resistance in the prior line of therapy (further defined below), etc.). These comparisons will be done via chi-square or Fisher's exact tests. We'll also assess primary versus acquired resistance to prior PD-1 inhibition in each arm as well. While not a formal stratification, in the interim and final analysis we'll also descriptively assess these subgroups between arms as well. |
Up to 2 years
|
|
ORR
Ramy czasowe: Up to 2 years
|
The response rate will be compared via chi-square or Fisher's exact tests between the 2 treatment arms using both the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria and also separately for the immune-modified RECIST criteria. |
Up to 2 years
|
|
Predictors of response
Ramy czasowe: Up to 2 years
|
Will correlate the baseline data (Epstein-Barr virus viral load, p16 immunohistochemistry status, smoking history, and PD-L1 score) with ORR data. For this analysis, logistic regression models will be assessed using the baseline data to predict binary response data. Odds ratios and 95% confidence intervals will be reported. Will also summarize the data using descriptive statistics and graphical methods. |
Up to 2 years
|
Współpracownicy i badacze
Sponsor
Sponsor
Śledczy
Śledczy
- Główny śledczy: Ari J Rosenberg, Alliance for Clinical Trials in Oncology
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Rozpoczęcie studiów
Zakończenie podstawowe (Szacowany)
Zakończenie podstawowe
Ukończenie studiów (Szacowany)
Ukończenie studiów
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Pierwszy wysłany
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia wysłana aktualizacja
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Dodatkowe istotne warunki MeSH
- Choroby Stomatognatyczne
- Nowotwory według lokalizacji
- Nowotwory
- Nowotwory według typu histologicznego
- Nowotwory głowy i szyi
- Nowotwory gruczołowe i nabłonkowe
- Rak
- Choroby otorynolaryngologiczne
- Nowotwory gardła
- Nowotwory otorynolaryngologiczne
- Choroby jamy nosowo-gardłowej
- Choroby gardła
- Nowotwory jamy nosowo-gardłowej
- Rak jamy nosowo-gardłowej
- Aminokwasy, peptydy i białka
- Białka
- Techniki śledcze
- Techniki laboratoryjne kliniczne
- Techniki i procedury diagnostyczne
- Diagnoza
- Czynniki biologiczne
- Przeciwciała, monoklonalne, humanizowane
- Przeciwciała, monoklonalne
- Przeciwciała
- Immunoglobuliny
- Immunoproteiny
- Białka krwi
- Globuliny w surowicy
- Globuliny
- Techniki chemii, analityczne
- Analiza widma
- Receptory, powierzchnia komórkowa
- Białka błony
- Antygeny
- Antygeny, powierzchnia
- Biomarkery
- Receptory, immunologiczne
- Antygeny, różnicowanie, limfocyt t
- Antygeny, różnicowanie
- Białka immunologiczne
- Kostymulujące i hamujące receptory komórek T
- Niwolumab
- Ipilimumab
- Prowadzenie okazów
- Spektroskopia rezonansu magnetycznego
- Cabozantinib
- Antygen CTLA-4
Inne numery identyfikacyjne badania
Inne numery identyfikacyjne badania
- NCI-2023-04469
- U10CA180821 (Grant/umowa NIH USA)
- NCI-2023-04469 (Identyfikator rejestru: CTRP (Clinical Trial Reporting Program))
- A092105 (Inny identyfikator: CTEP)
- A092105 (Inny identyfikator: Alliance for Clinical Trials in Oncology)
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Opis planu IPD
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
produkt wyprodukowany i wyeksportowany z USA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .